4^th International Conference on Clinical Microbiology and Infectious Diseases September 23-24, 2021 Berlin, Germany

Dr. Kevin Coombs obtained his BA in Biology and English from the State University of New York at Geneseo, and his PhD in Microbiology from the University of Texas at Austin, in 1986. After post-doctoral work at Harvard Medical School, he joined the faculty at the University of Manitoba in 1990. He is currently a Professor of Medical Microbiology, is a Research Scientist with the Manitoba Institute of Child Health, and is Assistant Dean of Research in the Faculty of Medicine.

His research interest mainly lies in Protein and nucleic acid interactions in nucleoprotein complexes, using a variety of model RNA viruses. His lab studies how these interactions change as a result of, and are modulated by, conformational transitions that occur during macromolecular assembly and disassembly, how these processes can be attenuated by anti-viral compounds, and how these processes contribute to pathogenesis in the host.

Petra Dersch graduated in Biology at the University of Konstanz. She continued her studies of Microbiology at the University of Konstanz and the Max-Planck-Institute for Terrestrial Microbiology Marburg and finished her PhD in 1995. After that, she worked as a postdoc in the laboratory of Dr. Ralph Isberg at the Tufts Medical School/Howard Hughes Medical Institute in Boston/USA. In 1998, back in Germany, she started as a Research Assistant with her own group at the Freie Universität Berlin. From 2003 - 2005, Petra Dersch was Junior Research Group Leader at the Robert Koch Institute Berlin. In 2005, she was appointed at the Technische Universität Braunschweig as Associate Professor in microbiology. Since 2008, Petra Dersch is Head of the Department of Molecular Infection Biology at the Helmholtz Centre for Infection Research in Braunschweig and holds a co-appointment as full professor in microbiology and infection biology at the Technische Universität Braunschweig. Petra Dersch is member of various boards, since 2012 she is elected member of the study section „Microbiology, Virology and Immunology“ of the German Research Foundation. She is member of the Central Commission for Biological Safety of the Federal Office of Consumer Protection and Food Safety Germany. Since 2016 she is one of the Vice Presidents of the DGHM (German Society for Hygiene and Microbiology). In 2013 Petra Dersch was awarded the Main Prize of the DGHM. Her main research field is molecular pathogenesis of enteric bacterial pathogens. She published more than 90 original papers in peer-reviewed international journals, reviews and book chapters.

Her main research field is molecular pathogenesis of enteric bacterial pathogens.

Joachim Wink has completed his Ph.D in 1985 from Frankfurt University. He then went to the pharmaceutical industry and started his career at the Hoechst AG where he was responsible for the strain collection and specialized in the cultivation and taxonomic characterization of Actinobacteria and Myxobacteria. During the years he was responsible for the strain library within the pharmaceutical research and a number of screening projects with Hoechst Marion Russel, Aventis and Sanofi. In the year 2005 he did his habilitation at the Carolo Wilhelma University of Braunschweig and 2012 he went to the Helmholtz Centre for Infection Research in Braunschweig where he founded the working group of the strain collection with its focus on Myxobacteria. Here he is now working on the isolation and taxonomic characterization of Myxobacteria and Actinobacteria as well as the analysis of their secondary metabolites with a focus on the antibiotics active ones. The Compendium of Actinobacteria on the homepage of the German Culture Collection is a permanent actualized working tool for people working with Actinobacteria which is prepared by him. He has published more than 50 papers on secondary metabolites and the taxonomy of the producing microorganisms in reputed journals, a number of reviews as well as book chapters and more than 35 patents. He is member of the editorial board of a number of international journals.

Dr Wink is working on the isolation and taxonomic characterization of Myxobacteria and Actinobacteria as well as the analysis of their secondary metabolites with a focus on the antibiotics active ones

PhD in Microbiology and Virology, with an high specialization in Molecular and Cellular Pathology, Arnolfo Petruzziello was born in Naples, Italy, where actually works as Head of the Laboratory of Virology and Molecular Biology “V. Tridente” at National Cancer Research IRCCS Italia- Fondazione “G. Pascale” in Naples. Professor of Microbiology, General Pathology and Clinical Microbiology for the University of Naples “Federico II”, he is also Quality Assurance Manager in the JACIE program for the autologous transplantation program of the Department of Haemathology and OECI (Organization of European Cancer Institutes) auditors. He is author of numerous scientific publications and member of the Editorial Board of several prestigious scientific Journals in Virology and Microbiology.

His fields of interests are mainly Virology and Molecular Biology, with particular reference to PCR for the diagnosis of HBV, HCV, HIV infections and EBV, HSV and CMV co-infections in the context of the transplantation program.

Ananda M. Chakrabarty, Ph.D., is a Distinguished University Professor at the University of Illinois College of Medicine at Chicago. While working at the Research & Development Center at General Electric Company in Schenectady, New York, he was awarded the ‘Scientist of the Year’ award in 1975 by Industrial Research Organization of the United States. This work led to the development of a genetically-manipulated microorganism that was the subject matter of a landmark decision from the Supreme Court of the United States that genetically engineered life forms are patentable. Dr. Chakrabarty has served as a consultant with the United Nations and was the founding member of a UNIDO Committee that proposed the establishment of the International Centre for Genetic Engineering & Biotechnology (ICGEB) based in Trieste, Italy, New Delhi, India, and Cape Town, South Africa. Dr. Chakrabarty has been a member of the Panel of Scientific Advisors, later called Council of Scientific Advisors, of ICGEB since its very inception. Dr. Chakrabarty has also been a member of the International Advisory Board of Chulabhorn Research Institute in Thailand, which is headed by the Princess Chulabhorn of Thailand, and a member of the Scientific Advisory Committee of the Department of Biotechnology (DBT) under the Ministry of Science & Technology, Govt. of India. He has received many awards, including the Distinguished Scientist Award from the United States Environmental Protection Agency (EPA), MERIT Award from NIH, U.S. Army Distinguished Service Award, Pasteur Award, Inventor of the Year Award, American Chemical Society Public Affairs Award, Procter and Gamble Environmental Biotechnology Award, European Union Eurydice Award given in Brussels in 2007, among others. He served the U.S. Govt. as members of various NIH study sections, member of the Board on Biology of the U. S. National Academy of Science, Committee on Biotechnology of the U.S. National Research Council, The Stockholm Environment Institute of Sweden, and on the Scientific Advisory Boards of many academic institutions such as Michigan Biotechnology Institute, Montana State University Center for Biofilm Research, Center for Microbial Ecology at the Michigan State University, and in Canada as a member of the Scientific Advisory Board of Canadian Bacterial Diseases Network based in Calgary, Canada. Dr. Chakrabarty also served NATO as a member of NIAG, NATO Industrial Advisory Group based in Brussels, Belgium. He was a member of the Board of Directors of Einstein Institute for Science, Health and the Courts, where he participated in judicial meetings involving contentious scientific issues. He was also involved in international judicial working conversations, where he served as a Scientific Advisor for meetings in Hawaii and Ottawa, Canada, organized by the Supreme Court of Canada. Dr. Chakrabarty’s current research involves development of anticancer and anti-retroviral agents from microbial sources. As part of CDG Therapeutics Inc. (www.cdgti.com) , he has developed candidate anticancer drugs such as azurin that can act on both the malarial parasite Plasmodium falciparum and the AIDS virus HIV-1 to combat co-infection, as well as drug candidates that can be used for the potential treatment of many forms of cancer including brain tumors. A chemically-synthesized 28 amino acid peptide derived from azurin, termed p28, has shown very little toxicity in 15 advanced stage cancer patients but significant beneficial effect, including partial and complete regression of tumors that were refractory to conventional drugs, in phase I human clinical trials in Chicago. He has also developed similar candidate anticancer drugs as part of an Indian company Amrita Therapeutics (www.amritatherapeutics.com). He was awarded the civilian Padma Shri award by the Government of India in 2007.

Dr. Chakrabarty’s current research involves development of anticancer and anti-retroviral agents from microbial sources. As part of CDG Therapeutics Inc. (www.cdgti.com) , he has developed candidate anticancer drugs such as azurin that can act on both the malarial parasite Plasmodium falciparum and the AIDS virus HIV-1 to combat co-infection, as well as drug candidates that can be used for the potential treatment of many forms of cancer including brain tumors. A chemically-synthesized 28 amino acid peptide derived from azurin, termed p28, has shown very little toxicity in 15 advanced stage cancer patients but significant beneficial effect, including partial and complete regression of tumors that were refractory to conventional drugs, in phase I human clinical trials in Chicago. He has also developed similar candidate anticancer drugs as part of an Indian company Amrita Therapeutics (www.amritatherapeutics.com). He was awarded the civilian Padma Shri award by the Government of India in 2007.